1. Home
  2. MXCT vs LUNG Comparison

MXCT vs LUNG Comparison

Compare MXCT & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$0.72

Market Cap

81.6M

Sector

Health Care

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.27

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXCT
LUNG
Founded
1999
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.6M
72.2M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
MXCT
LUNG
Price
$0.72
$1.27
Analyst Decision
Buy
Buy
Analyst Count
4
7
Target Price
$5.50
$5.38
AVG Volume (30 Days)
982.6K
727.7K
Earning Date
03-24-2026
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
7.64
EPS
N/A
N/A
Revenue
$33,026,000.00
$90,497,000.00
Revenue This Year
$18.61
$2.48
Revenue Next Year
$22.36
$18.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$0.64
$1.28
52 Week High
$2.96
$7.05

Technical Indicators

Market Signals
Indicator
MXCT
LUNG
Relative Strength Index (RSI) 38.93 33.99
Support Level $0.64 N/A
Resistance Level $0.87 $1.93
Average True Range (ATR) 0.06 0.11
MACD 0.00 -0.04
Stochastic Oscillator 28.02 0.79

Price Performance

Historical Comparison
MXCT
LUNG

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: